1. NICE/Scottish Intercollegiate Guidelines Network/Royal College of General Practitioners guidance 2021
2. Huang C, Wang Y, Li X, Ren L et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese
Center for Disease Control and Prevention. JAMA. 2020;323(13):1239.
4. Menni C, Valdes AM, Polidori L et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant
dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618.
5. Mizumoto K, Kagaya K, Zarebski A et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama,
Japan, 2020. Euro Surveill. 2020;25(10).
6. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med. 2020;173(5):362.
7. Ma Q, Liu J, Liu Q. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review
and Meta-analysis. JAMA Netw Open. 2021;4(12).
8. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. Ann Intern Med 2021; 174:655.
9. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020; 63:706.
10. Wang Y, Liu Y, Liu L, et al. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. J
Infect Dis. 2020;221(11):1770.
11. Centers for Disease Control and Prevention. COVID Data Tracker. Tr ends in United States COVID-19 Hospitalizations, Deaths, Emergenc y Department (ED) Visits, and Test Positivity by
Geographic Area. htt ps://covid.cdc.gov/covid-data-tracker/#trends_weeklyhospitaladmis sions_select_00 (Erişim 14 Haziran 2024).
12. Ahmad FB, Cisewski JA, Xu J,et al. COVID-19 Mortality Update – United States, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:493.
13. Nab L, Parker EPK, Andrews CD, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study
using the OpenSAFELY platform. Lancet Public Health 2023; 8:e364.
14. WHO. Estimating mortality from COVID-19: Scientific brief, 4 August 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci- Brief-Mortality-2020.1 (Accessed on August
13, 2020).
15. Meyerowitz-Katz G, Merone L. A systematic review and meta- analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis 2020; 101:138.
16. COVID-19 Forecasting Team. Variation in the COVID-19 infection- fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet 2022; 399:1469.
17. Garg S, Patel K, Pham H, et al. Clinical Trends Among U.S. Adults Hospitalized With COVID-19, March to December 2020 : A Cross- Sectional Study. Ann Intern Med 2021; 174:1409.
18. Xie Y, Choi T, Al-Aly Z. Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023. JAMA 2023; 329:1697.
19. Taylor CA, Patel K, Patton ME, et al. COVID-19-Associated Hospitalizations Among U.S. Adults Aged 65 Years – COVID-NET, 13 States, January-August 2023. MMWR Morb Mortal Wkly
Rep 2023; 72:1089.
20. Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of
30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet 2022; 400:1305.
21. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20:669.
22. Souza TH, Vanessa SL, Lee JH. COVID-19 and Children: Many Questions Yet To Be Answered. Ann Acad Med Singap2020 Aug;49(8):527-529.
23. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430.
24. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.
BMJ 2020; 369:m1966.
25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.
26. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26:1636.
27. Magleby R, Westblade LF, Trzebucki A, et al. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With
Coronavirus Disease 2019. Clin Infect Dis 2021; 73:e4197.
28. Yilmaz A, Marklund E, Andersson M, et al. Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ
Between Patients With Mild and Severe/Critical Coronavirus Disease 2019. J Infect Dis 2021; 223:15.
29. Dadras O, Afsahi AM, Pashaei Z, et al. The relationship between COVID-19 viral load and disease severity: A systematic review. Immun Inflamm Dis 2022; 10:e580.
30. Hogan CA, Stevens BA, Sahoo MK, et al. High Frequency of SARS- CoV-2 RNAemia and Association With Severe Disease. Clin Infect Dis 2021; 72:e291.
31. Kousathanas A, Pairo-Castineira E, Rawlik K, et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 2022; 607:97.
32. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med 2020; 383:1522.
33. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.
34. Wu Y, Kang L, Guo Z, et al. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta- analysis. JAMA Netw Open 2022; 5:e2228008.
35. Reiter ER, Coelho DH, French E, et al. COVID-19-Associated Chemosensory Loss Continues to Decline. Otolaryngol Head Neck Surg 2023; 169:1386.
36. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance – United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:759
37. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant
dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022; 399:1618.
38. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
JAMA 2020; 323:2052.
39. Tong JY, Wong A, Zhu D, et al. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2020;
163:3.
40. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ 2022;
378:e069503.
41. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-
analysis. Gastroenterology 2020; 159:81.
42. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.
Br J Dermatol 2020; 183:71.
43. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.
44. Surie D, Yuengling KA, DeCuir J, et al. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged 60 Years – IVY Network,
20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1083.
45. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324:799
46. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; 77:683.
47. Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection – United Kingdom and United States, March-A-
ugust 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1450.
48. www. cdc.gov/Mis-A case definition
49. Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open 2021; 4:e2126456.
50. Kubin CJ, McConville TH, Dietz D, et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health
Care-Associated Infections. Open Forum Infect Dis 2021; 8:ofab201.
51. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020;
173:268.
52. Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect
Dis 2022; 226:1593.
53. Davis HE, McCorkell L, Vogel JM. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology .Volume 21:March 2023. 133–146
54. Parotto M, Gyöngyösi M, Howe K. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. www.thelancet.com/respiratory Vol 11 August
2023